50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today ABEO ranks #12987 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Abeona Therapeutics Inc. Stock Forecast NASDAQ:ABEO

$0.73 (-3.57%)

Volume: 723k

Closed: Nov 26, 2021

Hollow Logo Score: -5.759

Abeona Therapeutics Inc. Stock Forecast

$0.73 (-3.57%)

Volume: 723k

Closed: Nov 26, 2021

Score Hollow Logo -5.759
Which way will ABEO go? Request
Key Stats
Beta 0.41
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 29 and the stock is currently not being overbought or oversold

Abeona Therapeutics Inc. stock downgraded from Sell Candidate to Strong Sell Candidate after Friday trading session.
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-12 Loss -20.22%

The Abeona Therapeutics Inc. stock price fell by -3.57% on the last day (Friday, 26th Nov 2021) from $0.76 to $0.73. During the day the stock fluctuated 7.63% from a day low at $0.71 to a day high of $0.76. The price has fallen in 8 of the last 10 days and is down by -21.98% for this period. Volume has increased on the last day by 490 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 723 thousand shares were bought and sold for approximately $527.52 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -40.59% during the next 3 months and, with a 90% probability hold a price between $0.37 and $0.51 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Abeona Therapeutics Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.77 and $0.87. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 09, 2021, and so far it has fallen -24.69%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Abeona Therapeutics Inc. gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0539 between high and low, or 7.63%. For the last week, the stock has had a daily average volatility of 7.83%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Abeona Therapeutics Inc. stock A Buy?

Abeona Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.759

Predicted Opening Price for Abeona Therapeutics Inc. of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$0.73 $0.73 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 06, 2021 "HC Wainwright" gave "$5.00" rating for ABEO. The price target was changed from $0.91 to 4.4%.

Volatility and Risk
Daily Average Volatility: 7.83 %
Overall Risk: Very High High Medium Low Very Low
7.83 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.77
Price: $0.73
No Support Found

ABEO Insider Trading Show all Trades



Last 100 transactions
Buy: 6 408 420 | Sell: 3 936 700 (Shares)
Date Action Amount Person Type
Nov 05, 2021 Sell 8 880 O'malley Brendan M. Common stock
Oct 15, 2021 Buy 300 000 Seshadri Vishwas Stock Option (right to buy)
Oct 15, 2021 Buy 50 000 Seshadri Vishwas Common stock
Oct 11, 2021 Sell 25 734 O'malley Brendan M. Common stock
Oct 08, 2021 Sell 22 763 O'malley Brendan M. Common stock
Show all Insider Trades


Last 100 transactions
Buy: 6 408 420 | Sell: 3 936 700 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.79 7.65 %
0.77 4.83 %
0.75 3.09 %
Current price: 0.73
Support 0.71 -2.55 %
0.70 -4.29 %
0.68 -7.11 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.91 24.66 %
0.81 10.97 %
0.77 5.07 %
Current price 0.73
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Abeona Therapeutics Inc.

Abeona Therapeutics Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemi... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE